Markers of Disease Progression in nAMD Patients
Veeral Sheth, MD, MBA, FASRS, FACS, offers clinical advice on marking disease progression in neovascular age-related macular degeneration (nAMD).
EP: 1.Overview of Anti-VEGF Treatments for AMD and DME
EP: 2.Barriers to Optimal Treatment Outcomes
EP: 3.Patient and Cross-Care Education Strategies for AMD and DME
EP: 4.Real-World Long-Term Safety Data of Anti-VEGF Agents
EP: 5.Treat and Extend Strategy for Anti-VEGF Injections
Now Viewing
EP: 6.Markers of Disease Progression in nAMD Patients
EP: 7.Significance of SRF vs IRF in nAMD
EP: 8.Current Treatment Options for nAMD
EP: 9.Managing Suboptimal Responders to Anti-VEGF Treatment
EP: 10.Applying CATT Study Results in Real World
EP: 11.Long-Term Treatment Experience with Aflibercept
EP: 12.Treat and Extend Strategy for Aflibercept
EP: 13.Prospective Therapies and Treatment Strategies for nAMD
EP: 14.Unique Challenges of DME Treatment
EP: 15.Key Findings of Protocol T Study
EP: 16.Key Findings of DRCR Protocol AC Study
EP: 17.Step Therapy for Patients With DME
EP: 18.Efficacy of Faricimab in Clinical Trails
EP: 19.High Dose Aflibercept as Emerging Therapy for Retinal Diseases
EP: 20.Other Emerging Retinal Disease Therapies
EP: 21.Emerging Gene Therapies for Retinal Diseases
EP: 22.Final Thoughts on Retinal Disease Treatments and Outcomes
Related Videos
Related Content
